Holly A. Black

Holly A. Black

Auto-generated profile, based on publicly available information

Holly A. Black

Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Cancer University of Edinburgh Edinburgh UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2024 in Science
Verified
Journal Article
Open access
DDDaniel O. Dodd
Daniel O. Dodd
SMSabrina Mechaussier
Sabrina Mechaussier
PYPatricia L. Yeyati
Patricia L. Yeyati
FMFraser McPhie
Fraser McPhie
JAJacob R. Anderson
Jacob R. Anderson
PMPleasantine Mill
Pleasantine Mill
Tubulin, one of the most abundant cytoskeletal building blocks, has numerous isotypes in metazoans encoded by different conserved genes. Whether these distinct isotypes form cell type– and context-specific microtubule structures is poorly understood. Based on a cohort of 12 patients with primary ciliary dyskinesia as well as mouse mutants, we identified and characterized variants in the TUBB4B isotype that specifically perturbed centriole and cilium biogenesis. Distinct TUBB4B variants differentially affected microtubule dynamics and cilia formation in a dominant-negative manner. Structure-function studies revealed that different TUBB4B variants disrupted distinct tubulin interfaces, thereby enabling stratification of patients into three classes of ciliopathic diseases. These findings show that specific tubulin isotypes have distinct and nonredundant subcellular functions and establish a link between tubulinopathies and ciliopathies.

1 March 2017 in Neurobiology of Aging
Verified
Journal Article
Open access
HBHolly A. Black
Holly A. Black
DLDanielle J. Leighton
Danielle J. Leighton
ECElaine M. Cleary
Elaine M. Cleary
ERElaine Rose
Elaine Rose
LSLaura Stephenson
Laura Stephenson
SCSiddharthan Chandran
Siddharthan Chandran
Genetic understanding of motor neuron disease (MND) has evolved greatly in the past 10 years, including the recent identification of association between MND and variants in TBK1 and NEK1. Our aim was to determine the frequency of pathogenic variants in known MND genes and to assess whether variants in TBK1 and NEK1 contribute to the burden of MND in the Scottish population. SOD1, TARDBP, OPTN, TBK1, and NEK1 were sequenced in 441 cases and 400 controls. In addition to 44 cases known to carry a C9orf72 hexanucleotide repeat expansion, we identified 31 cases and 2 controls that carried a loss-of-function or pathogenic variant. Loss-of-function variants were found in TBK1 in 3 cases and no controls and, separately, in NEK1 in 3 cases and no controls. This study provides an accurate description of the genetic epidemiology of MND in Scotland and provides support for the contribution of both TBK1 and NEK1 to MND susceptibility in the Scottish population.

15 December 2020 in PLOS Biology
Verified
Journal Article
Open access
PDF file
MRMartin A. M. Reijns
Martin A. M. Reijns
LTLouise Thompson
Louise Thompson
JAJuan Carlos Acosta
Juan Carlos Acosta
HBHolly A. Black
Holly A. Black
FSFrancisco J. Sanchez-Luque
Francisco J. Sanchez-Luque
AJAndrew P. Jackson
Andrew P. Jackson
With the ongoing COVID-19 (Coronavirus Disease 2019) pandemic, caused by the novel coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), there is a need for sensitive, specific, and affordable diagnostic tests to identify infected individuals, not all of whom are symptomatic. The most sensitive test involves the detection of viral RNA using RT-qPCR (quantitative reverse transcription PCR), with many commercial kits now available for this purpose. However, these are expensive, and supply of such kits in sufficient numbers cannot always be guaranteed. We therefore developed a multiplex assay using well-established SARS-CoV-2 targets alongside a human cellular control (RPP30) and a viral spike-in control (Phocine Herpes Virus 1 [PhHV-1]), which monitor sample quality and nucleic acid extraction efficiency, respectively. Here, we establish that this test performs as well as widely used commercial assays, but at substantially reduced cost. Furthermore, we demonstrate >1,000-fold variability in material routinely collected by combined nose and throat swabbing and establish a statistically significant correlation between the detected level of human and SARS-CoV-2 nucleic acids. The inclusion of the human control probe in our assay therefore provides a quantitative measure of sample quality that could help reduce false-negative rates. We demonstrate the feasibility of establishing a robust RT-qPCR assay at approximately 10% of the cost of equivalent commercial assays, which could benefit low-resource environments and make high-volume testing affordable.

8 August 2024 in Pediatric Pulmonology
Verified
Journal Article
Open access
HBHolly A. Black
Holly A. Black
SPSophie Marion de Proce
Sophie Marion de Proce
JCJose L. Campos
Jose L. Campos
AMAlison Meynert
Alison Meynert
MHMihail Halachev
Mihail Halachev
PMPleasantine Mill
Pleasantine Mill
Background: Primary ciliary dyskinesia (PCD) is a genetic disorder affecting motile cilia. Most cases are inherited recessively, due to variants in >50 genes that result in abnormal or absent motile cilia. This leads to chronic upper and lower airway disease, subfertility, and laterality defects. Given overlapping clinical features and genetic heterogeneity, diagnosis can be difficult and often occurs late. Of those tested an estimated 30% of genetically screened PCD patients still lack a molecular diagnosis. A molecular diagnosis allows for appropriate clinical management including prediction of phenotypic features correlated to genotype. Here, we aimed to identify how readily a genetic diagnosis could be made using whole genome sequencing (WGS) to facilitate identification of pathogenic variants in known genes as well as novel PCD candidate genes. Methods: WGS was used to screen for pathogenic variants in eight patients with PCD. Results: 7/8 cases had homozygous or biallelic variants in DNAH5 , DNAAF4 or DNAH11 classified as pathogenic or likely pathogenic. Three identified variants were deletions, ranging from 3 to 13 kb, for which WGS identified precise breakpoints, permitting confirmation by Sanger sequencing. WGS yielded identification of a de novo variant in a novel PCD gene TUBB4B . Conclusion: Here, WGS uplifted genetic diagnosis of PCD by identifying structural variants and novel modes of inheritance in new candidate genes. WGS could be an important component of the PCD diagnostic toolkit, increasing molecular diagnostic yield from current (70%) levels, and enhancing our understanding of fundamental biology of motile cilia and variants in the noncoding genome.